This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Ferry KV , Fink D , Johnson SW , Nebel S , Hamilton TC , Howell SB
Decreased cisplatin damage-dependent DNA synthesis in cellular extracts of mismatch repair deficient cells
Biochemical Pharmacology. 1999 Apr 15;57(8) :861-867
AbstractThe proficiency of both nucleotide excision repair (NER) and DNA mismatch repair (MMR) influences cellular sensitivity to cisplatin (cis-diamminedichloroplatinum). To gain further insight into how MMR may influence platinum drug sensitivity, the effect of loss of MMR on repair synthesis was measured in vitro by a commonly used method that relies on whole-cell extracts to drive [alpha-P-32]dATP incorporation into cisplatin-damaged plasmid DNA. Extracts evaluated include those from cells with or without functional hMLH1 (HCT116+ch2 versus HCT116+ch3, respectively) and hMSH2 (HEC59 versus HEC59+ch2, respectively). Loss of MMR in the HCT116 system was associated with a 2.8-fold reduction in cisplatin damage-specific DNA synthesis, whereas it was associated with a 3.0-fold reduction in the HEC59 system, suggesting that a decrease in the ability to repair cisplatin damaged DNA accompanies loss of MMR. An in vitro DNA excision assay that utilized a substrate containing a site-specific cisplatin adduct was performed. Using this highly NER-specific assay, no significant difference was apparent between the extracts derived from NER-proficient versus- deficient cells. These and other data lead us to suggest that the increase in apparent repair synthesis in platinum-damaged plasmids by extracts from MMR-proficient versus-deficient cellular extracts may reflect a distinct and possibly adverse DNA synthetic process rather than productive NER. BIOCHEM PHARMACOL 57;8:861-867, 1999. (C) 1999 Elsevier Science Inc.
NotesTimes Cited: 9 English Article 174FZ BIOCHEM PHARMACOL